e-mail submissions to [email protected]
Mortality reduction by breast-cancer screening
yield accorded with the trial results: one
This article, together with other reports
Julius Center for Health Sciences and Primary
Care, Utrecht Medical Center, HP D 01.335,
PB 85500, 3508 GA Utrecht, Netherlands(e-mail: [email protected])
Otto SJ, Fracheboud J, Looman CWN, et al.
mammography screening in Dutchmunicipalities and effect on breast-cancer
change in (disease-free) life expectancy.
mortality: a systematic review. Lancet 2003;
361: 1411–17.
National Evaluation Team for Breast Cancer
neither is the mortality reduction, which
Screening. Landelijke evaluatie vanbevolkingsonderzoek naar borstkanker in
8-year period of screening, 3·13 million
Nederlands, vol IX [National evaluation of
population screening for screening].
Visser D, Coebergh JWW, Schouten LJ, van Dijk JAAM (eds). Incidence of cancer in
the Netherlands 1997. Utrecht: Vereniging
women since 1980 was rather striking.
Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammographyscreening: updated overview of the Swedish
randomised trials. Lancet 2002; 359: 909–19.
Black WC, Haggstrom DA, Welch H. All cause mortality in randomized trials of
cancer screening. J Natl Cancer Inst 2002; 94: 167–73.
Sir—Suzie Otto and colleagues1conclude that changes in use ofadjuvant systemic therapy are an
introduction of population-basedmammography screening in the
Netherlands. They assumed that theproportion of node-positive patients
Incidence of and mortality from breast cancer in women aged 50–75 years in the
Before 1989, only first hospital-admissions of breast cancer as the primary diagnosis were available.
THE LANCET • Vol 362 • July 19, 2003 • www.thelancet.com
For personal use. Only reproduce with permission from The Lancet.
Nordic Cochrane Centre, Rigshospitalet Dept
7112, Blegdamsvej 9, DK-2100 Copenhagen,Denmark
Adri C Voogd, Jan Willem W Coebergh
municipalities and effect on breast-cancer
University, PO Box 616, 6200 MD Maastricht,
mortality: a systematic review. Lancet 2003;
361: 1411–17.
Registry, Comprehensive Cancer Centre South,
La Vecchia C. Cancer mortality in Europe,1990–1994, and an overview of trends from
1955 to 1994. Eur J Cancer 1999; 35:
Levi F, Lucchini F, Negri E, La Vecchia C.
municipalities and effect on breast-cancer
The fall in breast cancer mortality in Europe. Eur J Cancer 2001; 37: 1409–12.
mortality: a systematic review. Lancet 2003; 361: 1411–17.
handbooks of cancer prevention. Volume 7:
breast cancer screening. Lyon: IARC Press,
cancer in southeast Netherlands since 1984:
when tumours were receptor-positive.
a population-based study. Acta Oncol 1994; 33: 753–57.
Frisell J, Nordenskjöld B, Rutqvist LE.
screening: updated overview of the Swedish
randomised trials. Lancet 2002; 359:
Louwman WJ, Klokman WJ, Coebergh JW.
Excess mortality from breast cancer 20 years
normal. Br J Cancer 2001; 84: 700–03.
guidelines for adjuvant systemic treatment
of breast cancer at hospital level [in Dutch]. Ned Tijdschr Geneeskd 2000; 144: 1572–74.
for screening between 1991 and 1996.
endocrine treatment is difficult. A later
those aged 50–69 years (16·3% vs
THE LANCET • Vol 362 • July 19, 2003 • www.thelancet.com
For personal use. Only reproduce with permission from The Lancet.
Antibiotics Review Compiled from Dr. Naegerʼs lectures on 10/16/2007, 10/23/2007 & 10/30/2007. Meant to be a high-level outline of topics covered; obviously not exhaustive. Sulfonamides 1. sulfacetamide • Available in 10%, 15% and 30%; 10% & 15% not very effective; 30% used as a placebo (stings on insertion) therapy in certain patients. 2. trimethoprim • polytrim --Trime
For your sex: Use YOUR sex For your age: You are 43 years old Height: F: 5’2” M: 5’9” Weight: F: 185 lb M: 275 lb Current Medications: You are a diabetic. You use 2000 mg of Glucophage (Metformin) twice a day, 10 mg of Glucotrol (Glipizide) once a day, and 30mg of Actos (Pioglitazone Hydrochloride) once a day to control your blood sugars. Your Endocrinologi